BioNTech publishes proof-of-concept data for BNT211 CAR-T cell therapy
Category: #health  By Mateen Dalal  Date: 2020-01-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

BioNTech publishes proof-of-concept data for BNT211 CAR-T cell therapy

The report will contain data of CAR-T product candidate called BNT211, an autologous CAR-T cell therapy

BioNTech SE, a biotechnology firm based in Germany, recently announced a publication in Science regarding a therapeutic CAR-T approach for solid tumors that uses CAR-T cell amplifying RNA Vaccine, also called CARVac introduced by the company. The report offers preclinical proof-of-concept data for the company’s first CAR-T product candidate called BNT211 which is an autologous CAR-T cell therapy.

It essentially targets oncofetal antigen Claudin 6 (CLDN6) as well as outlines CARVac as an RNA vaccine approach that is widely applicable for the improvement of the efficacy of the CAR-T cell therapies.

Reportedly, CAR-T cell has exhibited considerable clinical efficacy in blood cancers but still tends to face challenges in regards with solid tumors that includes a limited number of identified cancer-specific solid tumors, insufficient persistence of CAR-T cells and inefficient CAR-T cell infiltration into solid tumors.

BioNTech has been aiming to overpower such hurdles by targeting the tumor-specific antigen expressed in several solid tumors, CLDN6, which when combined with an RNA vaccine will promote persistence, efficacy, and amplification of CAR-T cells in vivo.

CAR-T cell therapy combined with CARVac will be underlining the value of cross-platform synergies that would address major challenges for the development of cancer treatment.

Sources confirm that BioNTech has planned to commence Phase 1/2 clinical trial, its first-in-human trial for BNT211, later in the year in solid tumors such as testicular, lung cancer, ovarian and uterine. The manufacturing shall be conducted in-house at the state-of-the-art cell therapy facility BioNTech, which is GMP certified, to support the clinical trials of BNT211. The GMP plant is a certified cell therapy and manufacturing facility located in Idar-Oberstein, Germany, that has been operating since 1999.

BioNTech had initiated a capacity expansion at the facility in the year 2018 and it expects it to be completed by 2020.

 

Source Credit- https://investors.biontech.de/news-releases/news-release-details/biontech-announces-publication-preclinical-data-first-kind-car-t

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Microsoft to fix an active security flaw in Internet Explorer
Microsoft to fix an active security flaw in Internet Explorer
By Mateen Dalal

Microsoft, the renowned American tech giant, reportedly verified the presence of a security flaw that is affecting Internet Explorer (IE) and is being used by hackers. The company also said it is working to find a fix for this bug, which would be rel...

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
By Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Phar...